Male infertility. Male infertility
Conditions
Interventions
Intervention group: Letrozole (aromatase inhibitor), chemical formula: C17H11N5, concentration:2.5 mg , , Dosage: 2.5 mg per day, once a day, for 3 months, orally, made by Soha Pharma Company..
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: patients with idiopathic oligo/astheno/teratozoospermia patients with 25 to 45 years old testosterone to estradiol equal or less than 10
Exclusion criteria
Exclusion criteria: patients with seminal white blood cell concentration greater than 1millions per ml patients with drug, tobacco, or alcohol abusing patients with ongoing medical treatment or previous cancer radiotherapy or chemotherapy patients with varicocele patients with chromosomal abnormality
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm parameters. Timepoint: before and after 3 months administration of letrozole. Method of measurement: optical microscope.;Hormonal assay. Timepoint: before and after 3 months administration of letrozole. Method of measurement: using hormonal kits.;DNA integrity. Timepoint: before and after 3 months administration of letrozole. Method of measurement: flow cytometry.;Sperm intracellular ROS level. Timepoint: before and after 3 months administration of letrozole. Method of measurement: flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Soghra Bahmanpour
Shiraz University of Medical Sciences
Outcome results
None listed